Learning Hub

< BACK iPROLEPSIS 3rd Plenary meeting successfully closed Dec 14, 2023 Navigating Progress: Highlights from the 3rd iPROLEPSIS Plenary Meeting in Rotterdam On 12-13 December 2023 , the iPROLEPSIS consortium gathered for the 3rd plenary meeting in Rotterdam, the Netherlands. The agenda included: Four workshops External Advisory Board session Clinical studies overview, including PDPID study, Mast cells and optoacoustic-enabled joint and microvascular imaging (iPROLEPSIS-MOJMI) study, HPOS, and iPROLEPSIS integration General assembly session Overview of work packages with progress updates Strategic planning for the next steps. Four productive workshops were held: 1️⃣ PDPID study deployment and app: Ethical approval timeline SOP and OpenOpenClinica / eCRF App and cloud backend status UI/UX and translation timeline Usability testing 2️ ⃣ Digital biomarkers and data fusion Data retrieval roadmap Analysis methodologies Data fusion/modelling methodology MLOps solutions iPROLEPSIS-MOJMI-relevant biomarkers extraction 3️ ⃣ Technical workshop on digital ecosystem development Open issues and data collection monitoring Technical monitoring and orchestration needs MLOps technical aspects Alpha version of the digital ecosystem 4️ ⃣ Serious games co-creation session with patient partners Game design Stakeholders’ feedback We are grateful to patient representatives who joined the cocreation session . Their valuable input and perspectives are crucial for understanding the specific needs and requirements of those who will benefit from the iPROLEPSIS project. By actively involving patient representatives , we can ensure our solutions are patient-centric and tailored to their experiences and challenges. Thank you to Erasmus University Rotterdam for hosting the event. DSC03942.JPG IMG_7110.jpg iPROLEPSIS_cookies.JPG DSC03942.JPG 1/7 PREVIOUS NEXT

Learning Hub Explore resources to help you understand and manage psoriatic arthritis. Learning hub Key Facts Handbook News Feed Quizzes Search RSS News Feed Psoriatic Arthritis articles within Nature Reviews Rheumatology Journal of Psoriasis and Psoriatic Arthritis National Psoriasis Foundation

< BACK Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes Jun 27, 2024 Enhancing Mobility and Quality of Life through Agile Co-Designed Exergames for Psoriatic Arthritis We are pleased to announce our latest study, "Developing Exergames for Psoriatic Arthritis using Agile Storyboarding and Game Design Processes", presented at PETRA 2024. This research, a part of the Horizon Europe iPROLEPSIS project, focuses on creating Exergames to improve physical activity and well-being for individuals with Psoriatic Arthritis. Abstract Serious Games (SGs) offer significant potential in healthcare for disease assessment and intervention, enhancing patients’ quality of life. Exercise SGs, or Exergames, promote physical activity and mobility in a gamified environment, encouraging tailored exercises based on individual abilities and needs. Here, within the Horizon Europe iPROLEPSIS project that targets Psoriatic Arthritis (PsA), we describe the design process of Exergames to address PsA symptoms, including morning stiffness, impaired finger/hand and wrist functionality, and motor asymmetry. From a methodological point of view, the storyboarding technique was adopted to facilitate the visualization of the proposed Exergame scenarios, including the graphical user interface, interactive game elements, narratives, characters, and contexts related to the PsA condition. This approach has been implemented within an agile game development methodology, which includes gathering feedback early on to iteratively refine both the game ideas and prototype. Informed by the results of the game design via two agile sessions incorporating 25 participants (PsA patients, clinicians, technology developers, facilitators/observers), the current efforts are focused on developing the game prototypes and corresponding mock-ups, preparing them for upcoming clinical validation trials. The Exergames development lays the groundwork for an innovative framework to improve gross and fine motor symptoms in PsA patients. This framework could inform healthcare providers and policymakers about its potential inclusion in routine PsA management. Read more: https://dl.acm.org/doi/10.1145/3652037.3663939 Developing Exergames for Psoriatic Arthritis using Agile .pdf Download PDF • 1.70MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS, AI-PROGNOSIS & REBECCA: A Thematic Cluster on AI-Driven Digital Health Jul 17, 2025 Three EU-funded projects exploring real-world data, wearables, and personalised care in healthcare innovation Have you ever asked yourself how to make AI really effective along the patient journey? That was one of the first questions we asked ourselves when we launched our project. Along the way, we discovered we weren’t alone – many other research initiatives working with AI in healthcare were asking the same thing. That’s why we decided to take a step forward and create a cluster : a concrete way to collaborate, foster the impact of our solutions, and improve them through scientific exchange and an open science approach. AI-PROGNOSIS, iPROLEPSIS, and REBECCA – three EU-funded projects to advance patient-centric AI in healthcare. Focusing on Parkinson’s disease (PD), AI-PROGNOSIS is developing a suite of AI-powered tools for both patients and clinicians . These include early risk assessment, symptom monitoring, and medication support – based on real-world data from wearables and patient self-reports. It’s about enabling timely, data-driven decisions and bringing predictive analytics to the heart of primary care. iPROLEPSIS is building a comprehensive digital health ecosystem for psoriatic arthritis (PsA). It brings together a multisource biobank, a smartphone-based app powered by digital biomarkers and AI-driven predictive models, and an intervention module featuring therapeutic games, lifestyle coaching, and sleep support. The goal? To reshape the way we monitor and treat chronic inflammatory diseases through personalised mobile health solutions. Finally, REBECCA is working to improve long-term care for breast cancer survivors. By combining electronic health records with data from wearables and behaviour tracking , it generates real-world evidence on patients’ emotional, functional, and quality-of-life needs. Its explainable AI platform also supports caregivers and families via a dedicated app, empowering a more holistic approach to survivorship. What will we do together? We aim to contribute to the discussion on how AI-based digital health can support medical decision-making and real-time monitoring within daily hospital routines. I ntegrating AI into clinical practice is no easy task. Our solutions are designed to enable real-time health monitoring, informed decision-making, and disease management by leveraging biometric, behavioral, and clinical data –maximizing the impact along the patient journey. Another area of strong interest is the development of digital infrastructures that integrate wearable, clinical, behavioral, and environmental datasets. We believe these can be analyzed collectively through AI to generate real-world evidence and support both predictive and causal modeling – helping to guide research and inform treatment planning in more meaningful ways. Cluster.png Cluster.png 1/1 PREVIOUS NEXT

< BACK The miPROLEPSIS Joint Landmarker App Now Available for Android Devices on Google Play Store Sep 25, 2024 A New Tool for Assessing Physical Function in Psoriatic Arthritis As of 25 September 2024, the miPROLEPSIS Joint Landmarker app is available for Android devices on the Google Play Store. This app is a research app that accompanies the miPROLEPSIS app and aims to assess the physical functioning of people with Psoriatic Arthritis. More specifically, a set of 6 hand and body exercises are given and the user is asked to perform them in front of the smartphone camera. The app uses the collected videos to extract skeletal data (coordinates of skeletal joints), which are then sent to a cloud for further processing. Through the skeletal data processing, the aim is to identify whether a patient with Psoriatic Arthritis have difficulties in performing certain hand and body actions. miPROLEPSIS Joint Landmarker - Apps on Google Play 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS 3rd Plenary Meeting Nov 30, 2023 iPROLEPSIS 3rd Plenary Meeting in Rotterdam: 12-13 December 2023 On 12-13 December 2023, iPROLEPSIS partners will meet in Rotterdam for the third plenary meeting. The agenda includes workshops on the PDPID study, digital biomarkers, technical ecosystem development, serious games co-creation, an External Advisory Board session, and more. Stay tuned for updates on our progress! iPROLEPSIS 3rd Plenary meeting (1).png iPROLEPSIS 3rd Plenary meeting (1).png 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Newsletter No. 8 Apr 28, 2025 Latest News from iPROLEPSIS Welcome to the eighth edition of the iPROLEPSIS newsletter, where we share the latest updates and progress from the project. iPROLEPSIS project newsletter Issue No. 8_Apr 2025 .pdf Download PDF • 3.38MB 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Website Goes Live Mar 26, 2023 The website of the iPROLEPSIS project is finalised and available online. The website of the iPROLEPSIS project is finalised and available online. The website presents the key facts and figures about the project, and will be frequently updated about the project results, events, and key plans. News & Events iPROLEPSIS - news.png News & Events iPROLEPSIS - news.png 1/1 PREVIOUS NEXT

< BACK Innovative Digital Solutions for Psoriatic Arthritis: A Spotlight on the iPROLEPSIS Project by Prof. Leontios Hadjileontiadis Feb 14, 2024 Empowering Patients, Pioneering Solutions, and Bridging Gaps in Psoriatic Arthritis Knowledge Prof. Leontios Hadjileontiadis, the coordinator of the iPROLEPSIS project, shares how the iPROLEPSIS project addresses psoriatic arthritis research . iPROLEPSIS aims to identify triggers behind the transition from psoriasis to psoriatic arthritis, employing digital models and everyday devices like smartphones and smartwatches to understand disease dynamics. Beyond research, iPROLEPSIS introduces practical solutions such as biAURA for pain relief through sound and serious games targeting exercise, emotion, nutrition, and pain management. Collaborating with 15 partners, including patient advocates, iPROLEPSIS adopts a co-creation approach , bridging technological innovation with real-world healthcare practices. Focusing on predictive and preventive healthcare, iPROLEPSIS strives to fill the knowledge gap surrounding psoriatic arthritis, transforming the research landscape. Watch the full interview: leontios_edited.jpg leontios_edited.jpg 1/1 PREVIOUS NEXT

< BACK iPROLEPSIS Project Presented to Sonova International Sep 10, 2024 Innovative Approaches in Digital Biomarkers In September 2024, the iPROLEPSIS project was presented at a meeting with Sonova International. This event included a series of insightful presentations, highlighting the project's focus on developing digital biomarkers. The iPROLEPSIS concept and vision were shared, showcasing the innovative approaches the project is undertaking. We extend our gratitude for the engaging discussions during the “Sonova-AUTH Day,” hosted by the Signal Processing & Biomedical Technology Unit at Aristotle University of Thessaloniki. The event featured a range of topics, including advancements in digital biomarkers, innovations in hearing instruments by Sonova Group, ear-EEG technology, auditory processing disorders, and insights into the hearing aid market in Greece. 1/2 PREVIOUS NEXT

< BACK Exploring the iPROLEPSIS Project: Insights from J. Luime Sep 17, 2024 Innovative Approaches to Monitoring and Managing Psoriatic Arthritis Jolanda Luime, senior researcher and project partner from Erasmus MC (the Netherlands), shares insights on the iPROLEPSIS project. The iPROLEPSIS project represents a significant advancement in the field of psoriatic arthritis research. By leveraging cutting-edge technology, including smartphones and data analysis, iPROLEPSIS aims to transform how we measure and understand psoriatic arthritis activity. Traditional methods of tracking psoriatic arthritis often fall short in capturing the full scope of the disease’s impact. iPROLEPSIS seeks to address this gap by exploring new and innovative approaches. The project uses advanced technology to monitor movement patterns and other key indicators of disease activity, offering a more comprehensive view of how the condition affects patients on a daily basis. One of the core objectives of iPROLEPSIS is to empower patients with better tools for managing their condition. By providing more detailed insights into disease activity, the project aims to help patients make informed decisions about their health and potentially prevent disease flares before they occur. This proactive approach has the potential to significantly improve the quality of life for those living with psoriatic arthritis. In addition to benefiting patients, iPROLEPSIS aims to to support clinicians by offering more accurate and actionable data. With better insights into disease activity and treatment effectiveness, healthcare providers can make more informed decisions regarding medication adjustments and overall treatment strategies. This not only enhances patient care but also helps streamline clinical practices, making the process more efficient and effective. Through the iPROLEPSIS project, the aim is to provide patients and clinicians with the tools they need to better understand and manage psoriatic arthritis, ultimately improving both patient outcomes and clinical practices. 1/1 PREVIOUS NEXT

< BACK Khalifa University Features iPROLEPSIS in Research News Jun 2, 2025 AI, Apps and Arthritis: A Digital Leap in Psoriatic Care Khalifa University Research News has featured iPROLEPSIS in a new article showcasing our mission to transform psoriatic arthritis care through digital innovation. Led by Prof. Leontios Hadjileontiadis, iPROLEPSIS is a Horizon Europe-funded initiative using artificial intelligence, wearable technology, and mobile health apps to shift care from reactive treatment to proactive prevention . By combining explainable AI with real-world patient data, we aim to support earlier diagnosis , personalized treatment , and patient-centered digital tools that empower both clinicians and individuals living with psoriatic arthritis. Read the full article on Khalifa University website: https://www.ku.ac.ae/ai-apps-and-arthritis-a-digital-leap-in-psoriatic-care Hero section.png Hero section.png 1/1 PREVIOUS NEXT